Top news of the week: 25.07.2022.
Money on the Move: Auron, Frontera, Immunocore and More Reel in New Funds (Updated)
Auron Therapeutics reels in $48 million to identify novel AI-based cancer targets, Frontera scoops up $160 million for AAV gene therapy and tech manufacturing and MMI scores $75 million for ...
Parents Become Drug Developers to Save Their Children’s Lives
Families affected by ultra-rare diseases are starting their own companies to speed the development of treatments for their kids, venturing into territory that traditional drugmakers deem ...
Versanis Taps Biotech Veteran Pruzanski to Drive Obesity Drug Forward
On Wednesday, Versanis appointed Intercept Pharmaceuticals veteran Mark Pruzanski as chairman and chief executive officer, and John Maraganore has taken a seat on the board.
Biotech Co.'s Phase 3 Trial First to Get Grant
A U.K.-based junior biotech co. has been approved for a grant to fund most of a Phase 3 study exploring the use of psychedelics to treat alcohol use disorder.
Trial Results Show New Drug Improves Dry Eye Symptoms Research Report
These study data from Aldeyra Therapeutics Inc. solidified the therapeutic's path to filing a new drug application, potentially in Q3/22.
How to Face Compliance Challenges in a Regulated Environment
There’s no question that complying with pharmaceutical, biotech and medical device rules and regulations costs money. In addition to the expenses that occur as a result of hiring and ...